Mahesh J. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mahesh J. Patel has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- William E. Kraus
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA
2 shared publications Amanda Cummings
Trinity College of Arts and Sciences, Duke University, Durham, NC
1 shared publicationAmit Khera
Division of Cardiology, The University of Texas-Southwestern Medical Center, Dallas, TX
1 shared publicationBradi Granger
Division of Cardiovascular Medicine, Duke University, Durham, NC
1 shared publicationCris A. Slentz
Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina
1 shared publicationDaniel R. Bensimhon
LeBauer HeartCare, Greensboro, NC
1 shared publication
Latest Publications
- 25 August 2013
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 15 (6) , 681-695
Inflammation and Atherosclerosis: Disease Modulating Therapies
Opinion statement Advances in the mechanistic understanding of atheroma initiation, repair, progression, and rupture have solidified the pivotal role played by the immune system in the pathophysiology of atherosclerotic vascular disease. These mechanistic findings have been extended into humans, with a strong evidence basis for the independent association between elevated blood markers of inflammation and future cardiovascular (CV) events. Investigations with statins as well as more conventional anti-inflammatory medications provide indirect evidence to support the concept that modifying immune responses can improve CV outcomes; however, robust evidence to support the use of anti-inflammatory treatment strategies to manage atherosclerotic vascular disease is still lacking. Such evidence may emerge from a new wave of clinical trials directly exploring the effects of targeted immune modulation on CV risk. These trials will provide key additional insights into atherosclerosis and will help determine the fate of immune modulation as a new treatment strategy in atherosclerotic vascular disease.
- 25 August 2013
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 15 (6) , 681-695
Inflammation and Atherosclerosis: Disease Modulating Therapies
Opinion statement Advances in the mechanistic understanding of atheroma initiation, repair, progression, and rupture have solidified the pivotal role played by the immune system in the pathophysiology of atherosclerotic vascular disease. These mechanistic findings have been extended into humans, with a strong evidence basis for the independent association between elevated blood markers of inflammation and future cardiovascular (CV) events. Investigations with statins as well as more conventional anti-inflammatory medications provide indirect evidence to support the concept that modifying immune responses can improve CV outcomes; however, robust evidence to support the use of anti-inflammatory treatment strategies to manage atherosclerotic vascular disease is still lacking. Such evidence may emerge from a new wave of clinical trials directly exploring the effects of targeted immune modulation on CV risk. These trials will provide key additional insights into atherosclerosis and will help determine the fate of immune modulation as a new treatment strategy in atherosclerotic vascular disease.
- 1 October 2011
- Published by Elsevier in The American Journal of Medicine
- Vol. 124 (10) , 908-910
Improving Cardiac Rehabilitation Referral Patterns Using Computerized Physician Order Entry Systems
- 1 October 2011
- Published by Elsevier in The American Journal of Medicine
- Vol. 124 (10) , 908-910
Improving Cardiac Rehabilitation Referral Patterns Using Computerized Physician Order Entry Systems
- 1 October 2011
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 111 (4) , 1211-1217
Metabolic deterioration of the sedentary control group in clinical trials
Randomized clinical trials of exercise training regimens in sedentary individuals have provided a mechanistic understanding of the long-term health benefits and consequences of physical activity and inactivity. The sedentary control periods from these trials have provided evidence of the progressive metabolic deterioration that results from as little as 4–6 mo of continuing a physically inactive lifestyle. These clinical trials have also demonstrated that only a modest amount of physical activity is required to prevent this metabolic deterioration, and this amount of physical activity is consistent with current physical activity recommendations (150 min/wk of moderate intensity physical activity). These recommendations have been issued to the general population for a vast array of health benefits. While greater adherence to these recommendations should result in substantial improvements in the health of the population, these recommendations still remain inadequate for many individuals. An individual's physical activity requirements are influenced by such factors as an individual's diet, nonexercise physical activity patterns, genetic profile, and medications. Improving the understanding of how these factors influence an individual's physical activity requirements will help advance the field and help move the field toward the development of more personalized physical activity recommendations.
- 1 October 2011
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 111 (4) , 1211-1217
Metabolic deterioration of the sedentary control group in clinical trials
Randomized clinical trials of exercise training regimens in sedentary individuals have provided a mechanistic understanding of the long-term health benefits and consequences of physical activity and inactivity. The sedentary control periods from these trials have provided evidence of the progressive metabolic deterioration that results from as little as 4–6 mo of continuing a physically inactive lifestyle. These clinical trials have also demonstrated that only a modest amount of physical activity is required to prevent this metabolic deterioration, and this amount of physical activity is consistent with current physical activity recommendations (150 min/wk of moderate intensity physical activity). These recommendations have been issued to the general population for a vast array of health benefits. While greater adherence to these recommendations should result in substantial improvements in the health of the population, these recommendations still remain inadequate for many individuals. An individual's physical activity requirements are influenced by such factors as an individual's diet, nonexercise physical activity patterns, genetic profile, and medications. Improving the understanding of how these factors influence an individual's physical activity requirements will help advance the field and help move the field toward the development of more personalized physical activity recommendations.
- 1 June 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (6) , 1001-1009
Evaluation of coronary artery calcium screening strategies focused on risk categories: The Dallas Heart Study
- 1 June 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (6) , 1001-1009
Evaluation of coronary artery calcium screening strategies focused on risk categories: The Dallas Heart Study